CYP19A1 and endocrine system disorder: The two other patent applications, filed in 2013 and 2015, report the use of AD and ADD in pharmaceutical compounds that act as aromatase enzyme inhibitors and in the treatment of endocrine diseases, hormonal disorders, cancer, and other estrogen-related pathologies.